CEP63

Across TCGA pan-cancer cohorts, CEP63 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CEP63 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CEP63 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP63 expression acts as an unfavorable survival marker.

HNSC, STAD, and LUAD are the cancer types where CEP63 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.236	0.688	.004	18	view →
STAD	OS	Median	All	0.202	0.669	.012	15	view →
LUAD	OS	Median	III,IV	0.068	0.680	<.001	12	view →
LIHC	DFS	Median	All	0.081	0.555	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.240	0.643	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CEP63–HNSC (OS)

Open the HNSC breakdown →